Thanks to the specific technology developed by ERYtech Pharma, a powerful platform has been validated:
-
to develop new products with long circulating action with no release of the compounds : bio-reaction into the red cells for Graspa®, oxygen-hemoglobin affinity reduction for Grara.
-
to rapidly target specific cells involved in the erythrophagocytosis (Kupffer cells, dendritic cells, macrophages) : intra cells gene silencing for Gr- Rnai, in situ immuno-stimulation of dendritic cells for GrVax.
